AtriCure price target raised to $57 from $52 at Canaccord

Canaccord analyst William Plovanic raised the firm’s price target on AtriCure to $57 from $52 and keeps a Buy rating on the shares. The firm said they reported full Q4 revenue of $106.5M, in line with the company’s preannouncement in early January and ahead of Canaccord’s projected Q4 revenue of $102.0M at the time of the preannouncement.